Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

Stopped early · Phase 4

Conditions studied: Acne Vulgaris

In brief

Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris

Key facts

Study ID

NCT00829049

Run by

Allergan

People needed

165

Starts

2007-10-01

Expected to finish

2008-10-01

Last updated by the study team

2012-09-12

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Facial acne vulgaris characterized by the following: 25-100 facial inflammatory lesions (papules plus pustules); and 40 or more non-inflammatory lesions (open/closed comedones)); stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or less facial nodules and/or cysts (diameter of 1cm or greater).
• Female subjects of childbearing potential must have a negative urine pregnancy test at baseline and practice reliable method of contraception throughout the study.

You may not qualify if…

• Non-compliance with washout period
• Skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris
• Allergy or sensitivity to any component of the test medications
• Cosmetic or surgical procedure complementary to the treatment of facial acne within 14 days of the baseline visit

Where it is running

• Study site — Fremont, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.